A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

TerminatedOBSERVATIONAL
Enrollment

26

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

May 18, 2020

Study Completion Date

May 18, 2020

Conditions
AmyloidosisLeukocyte Chemotactic Factor 2 Amyloidosis
Trial Locations (31)

14080

Clinical Trial Site, México

21200

Clinical Trial Site, Mexicali

21205

Clinical Trial Site, Baltimore

43210

Clinical Trial Site, Columbus

46202

Clinical Trial Site, Indianapolis

48201

Clinical Trial Site, Detroit

55902

Clinical Trial Site, Rochester

60611

Clinical Trial Site, Chicago

77004

Clinical Trial Site, Houston

77030

Clinical Trial Site, Houston

78212

Clinical Trial Site, San Antonio

80210

Clinical Trial Site, Denver

80230

Clinical Trial Site, Culiacán

84790

Clinical Trial Site, St. George

85259

Clinical Trial Site, Scottsdale

85724

Clinical Trial Site, Tucson

87106

Clinical Trial Site, Albuquerque

97239

Clinical Trial Site, Portland

02118

Clinical Trial Site, Boston

Unknown

Clinical Trial Site, Al Mansurah

Clinical Trial Site, Alexandria

Clinical Trial Site, Asyut

Clinical Trial Site, Cairo

Clinical Trial Site, Chandigarh

Clinical Trial Site, Ludhiāna

Clinical Trial Site, Manipal

Clinical Trial Site, Nadiād

Clinical Trial Site, Tamil Nadu

Clinical Trial Site, Kuala Lumpur

Clinical Trial Site, Monterrey

Clinical Trial Site, London

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY